<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01068132</url>
  </required_header>
  <id_info>
    <org_study_id>2008-007524-25</org_study_id>
    <nct_id>NCT01068132</nct_id>
  </id_info>
  <brief_title>Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.</brief_title>
  <official_title>Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab. An Italian Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regione Lombardia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>A.O. Ospedale Papa Giovanni XXIII</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Regione Lombardia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Italian, multicentre, non comparative trial in patients with advanced Colorectal&#xD;
      Cancer(CRC)and KRAS wild-type, defined by molecular evaluation.&#xD;
&#xD;
      Patients will receive Cetuximab + FOLFIRI until disease progression, unacceptable toxicity&#xD;
      developed or patient refusal.&#xD;
&#xD;
      The aim of this study is to assess the prognostic role of PTEN in terms of Progression free&#xD;
      survival.&#xD;
&#xD;
      Although the role of Cetuximab as first line treatment in metastatic CRC will be soon&#xD;
      established, it is still unclear which is the best schedule for Cetuximab and the role of&#xD;
      biological factors in order to select the most appropriate subset of pts for recommending&#xD;
      Cetuximab. The data supporting a benefit of Cetuximab in KRAS wild-type pts open the&#xD;
      perspective to study the role of other molecular markers in this subset of pts.&#xD;
&#xD;
      On the basis of these considerations this study is aimed at testing a different schedule of&#xD;
      Cetuximab and better characterize the prognosis of pts for which Cetuximab is appropriate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pts meeting eligibility criteria will be registered, providing the availability of material&#xD;
      for molecular analysis. Tumour specimens and blood sample will be collected to perform&#xD;
      genomic, ICH and proteomic analyses in order to identify the molecular characteristics of&#xD;
      tumour.&#xD;
&#xD;
      After the availability of KRAS evaluation, only the data of KRAS wild-type pts will be&#xD;
      collected.&#xD;
&#xD;
      Access to registration system will be allowed via web.&#xD;
&#xD;
      Patients,KRAS wild-type receive:&#xD;
&#xD;
      - Cetuximab+FOLFIRI: cetuximab 500 mg/ m² starting dose, following everytwo- week doses of&#xD;
      500 mg/ m², given d1, followed after 1 hour by FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV&#xD;
      100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an&#xD;
      intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU&#xD;
      bolus injection on days 1 and 2&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>untill 48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>untill 48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab+FOLFIRI: cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1, followed after 1 hour by FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1,</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Signed written informed consent for biological analysis (all pts)&#xD;
&#xD;
          -  Signed written informed consent for enrolment (pts with KRAS wild type)&#xD;
&#xD;
          -  Male or female aged &gt; or = 18 years&#xD;
&#xD;
          -  Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum&#xD;
&#xD;
          -  KRAS evaluation availability with wild-type result&#xD;
&#xD;
          -  Metastatic CRC not suitable for curative-intent resection&#xD;
&#xD;
          -  Availability of tumour samples (or able and willing to provide tumour sample) and&#xD;
             blood for biological analysis&#xD;
&#xD;
          -  Presence of at least one lesion measurable unidimensionally by computed tomography&#xD;
             (CT) scan or magnetic resonance imaging (MRI). (index lesion(s) must not lie within an&#xD;
             irradiated area)&#xD;
&#xD;
          -  Eastern cooperative oncology group-performance status (ECOG-PS) &lt;2&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Brain metastasis (known or suspected)&#xD;
&#xD;
          -  Previous chemotherapy for metastatic CRC (any). Adjuvant therapy is allowed if the&#xD;
             chemotherapy treatment free interval is &gt; 6 months&#xD;
&#xD;
          -  Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to study&#xD;
             entry&#xD;
&#xD;
          -  Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not&#xD;
             indicated in the study protocol&#xD;
&#xD;
          -  Any investigational agent(s) within 4 weeks prior to entry&#xD;
&#xD;
          -  Previous exposure to HER-axis -pathway targeting therapy&#xD;
&#xD;
          -  Leucocytes &lt;3.0 x 109/L and neutrophils &lt;1.5 x 109/L, platelets &lt;100 x 109/L, and&#xD;
             hemoglobin &lt;9 g/dL&#xD;
&#xD;
          -  Bilirubin level either normal or &gt;1.5 x ULN&#xD;
&#xD;
          -  ASAT and ALAT &gt;2.5 x ULN (&gt;5 x ULN if liver metastasis are present)&#xD;
&#xD;
          -  Serum creatinine &gt;1.5 x ULN&#xD;
&#xD;
          -  Clinically relevant coronary artery disease or a history of a myocardial infarction&#xD;
             within the last 12 months&#xD;
&#xD;
          -  Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease&#xD;
&#xD;
          -  Pre-existing neuropathy &gt; grade 1&#xD;
&#xD;
          -  Known grade 3 or 4 allergic reaction to any of the components of the treatment&#xD;
&#xD;
          -  Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of&#xD;
             the cervix. (Pts with a previous malignancy but without evidence of disease for &gt; or&#xD;
             equal 5 years will be allowed to enter the trial)&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Inadequate contraception (male or female pts) if of childbearing or procreational&#xD;
             potential&#xD;
&#xD;
          -  Known drug abuse/ alcohol abuse&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Medical or psychological condition which in the opinion of the investigator would not&#xD;
             permit the patient to complete the study or sign meaningful informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Labianca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Ospedale Papa Giovanni XXIII</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Armando Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale di Treviglio e Caravaggio</name>
      <address>
        <city>Treviglio</city>
        <state>Bergamo</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istututo Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20086</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Morelli Sondalo</name>
      <address>
        <city>Sondalo</city>
        <state>Sondrio</state>
        <zip>23035</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Saronno</name>
      <address>
        <city>Saronno</city>
        <state>Varese</state>
        <zip>21047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Sondrio</name>
      <address>
        <city>Sondrio</city>
        <zip>23100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>February 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2010</study_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>KRAS</keyword>
  <keyword>PTEN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

